The FDA has authorized Rejoyn — the first prescription digital therapeutic app specifically designed for major depressive disorder. Here’s everything you need to know about how it works, what the clinical trial showed, and what it means for the future of mental health care.

---

In a groundbreaking development for mental health care, the U.S. Food and Drug Administration (FDA) cleared Rejoyn on March 30, 2024 — making it the first FDA-authorized prescription digital therapeutic specifically designed to treat major depressive disorder (MDD). This innovative approach combines technology with evidence-based therapy, offering a new avenue for individuals seeking relief from depression symptoms. If you’ve been following how deeply depression can intersect with other health conditions, our earlier piece on Chronic Pain and Depression: Breaking Down the Connection gives a helpful backdrop for understanding just how complex and far-reaching MDD can be.

---

What Is Rejoyn?

Rejoyn is a smartphone application developed by Click Therapeutics in collaboration with Otsuka America Pharmaceutical, Inc. Classified as a medical device (not a drug), Rejoyn is designed to be used alongside traditional antidepressant medications — not as a replacement. It provides a six-week program that includes cognitive-behavioral therapy (CBT)–based lessons and brain-training exercises, aiming to enhance emotional control and reduce depression symptoms by leveraging the brain’s natural ability to reorganize itself, known as neuroplasticity.

While Rejoyn is the first of its kind for MDD, other prescription digital therapeutics already exist for conditions like insomnia, ADHD, and substance use disorders. Rejoyn is specifically the first authorized for depression.

---

How Does Rejoyn Work?

Rejoyn’s program comprises daily sessions that blend CBT-based lessons with Emotional Faces Memory Task (EFMT) exercises. These EFMT exercises are thought to stimulate brain regions associated with emotion processing — such as the amygdala and the dorsolateral prefrontal cortex — though these precise regional effects are based on the proposed mechanism from trial materials rather than large-scale imaging studies. If you’re curious about how psychotherapy-based approaches are being applied beyond traditional mental health settings, our post on Psychotherapy Approaches for Metabolic Disorders explores how CBT principles are expanding across medical disciplines.

By engaging these areas, the app seeks to gradually reshape how the brain processes emotions, thereby alleviating depressive symptoms over the course of the program.

Users are guided through the program with personalized reminders and messaging, ensuring consistent engagement. The app’s flexible design allows users to complete sessions at their own convenience, making it a practical addition to an existing treatment regimen.

---

Clinical Trial and FDA Approval

The FDA’s authorization of Rejoyn was based on data from the Mirai study — a 13-week, multicenter, randomized, sham-controlled trial involving 386 participants aged 22 to 64 with MDD who were already on antidepressant medication but experiencing an inadequate response.

Participants were assigned to either the Rejoyn app or a sham control app (both installed on participants’ own smartphones). The study found that individuals using Rejoyn showed greater improvement in depression symptom severity compared to the control group. Improvements were observed across multiple validated scales:

• Montgomery-Åsberg Depression Rating Scale (MADRS)
• Patient Health Questionnaire-9 (PHQ-9)
• Clinical Global Impression – Severity scale (CGI-S)

It is worth noting that while the Rejoyn group showed greater improvement across these measures, not all endpoints reached statistical significance in the primary analysis — something important to keep in mind when interpreting the results.

Regarding safety, no serious adverse events were specifically attributed to Rejoyn during the trial, and its overall adverse-event profile was similar to that of the sham control app — making it a generally safe adjunctive option, though long-term real-world safety data are still emerging.

---

Advantages of Rejoyn

• Accessibility: Being a smartphone app, Rejoyn offers a convenient option for patients who face geographic, financial, or scheduling barriers to in-person therapy. This ties directly into a larger conversation we’ve had on Breaking the Stigma: Why It’s Okay to Seek Therapy — accessibility is one of the biggest levers in closing the mental health treatment gap.
• Personalization: The app provides tailored reminders and messaging, enhancing user engagement and adherence throughout the six-week program.
• Complementary Treatment: Designed explicitly as an adjunct to existing antidepressant medications and clinician-managed care — it adds to the toolkit without replacing professional treatment. As we explored in Therapy: The Need of the Hour for Lifestyle Modification, structured therapeutic tools work best when layered with professional guidance, not used in isolation.
• Favorable Safety Profile: No serious adverse events were directly attributable to Rejoyn in the trial; its side-effect profile was comparable to the sham app, making it a generally well-tolerated option.

---

Considerations and Limitations

While Rejoyn is a promising step forward in digital therapeutics, a few important limitations deserve attention:

• Prescription Requirement: Rejoyn is a prescription-only app. You cannot simply download and use it — a consultation with a licensed healthcare provider is necessary to obtain access.
• Adjunctive Use Only: The app is intended to complement, not replace, antidepressant treatments and professional therapy. It should not be seen as a standalone solution for depression.
• Insurance Coverage: As of now, third-party coverage and reimbursement pathways for Rejoyn remain limited and are still evolving — and may vary by insurer and region.
• Emerging Long-Term Data: The Mirai trial was 13 weeks long. Long-term real-world effectiveness and safety data beyond the trial period are still being gathered.

---

The Bottom Line

The FDA’s authorization of Rejoyn marks a meaningful milestone in the integration of technology and mental health treatment. By offering a scientifically-backed, accessible, and user-friendly tool for patients already on antidepressants, Rejoyn has the potential to meaningfully improve the management of major depressive disorder — particularly for those who haven’t seen full relief from medication alone. For a broader look at where treatment innovation is heading for younger populations, our piece on Innovative Approaches to Treating Depression in Adolescents is a great companion read. And if you’re trying to understand why depression rates are climbing across age groups in the first place, Understanding the Rise in Teen Anxiety and Depression: Causes and Solutions offers important context.

That said, it is not a magic fix, and it isn’t meant to be used in isolation. The strongest outcomes will come when Rejoyn is used as part of a comprehensive, clinician-guided treatment plan.

As digital therapeutics continue to mature, tools like Rejoyn may play an increasingly important role in how we think about — and treat — mental health at scale.

---

References

1. Rejoyn: First App Cleared by FDA for Depression — Psychiatry Online
2. Rejoyn: An Add-On Prescription App for Depression Symptoms — Rejoyn Official Website
3. First Smartphone App to Gain FDA Approval for Depression — American Academy of Family Physicians
4. Otsuka and Click Therapeutics Announce FDA Clearance of Rejoyn — Otsuka America Pharmaceutical, Inc.
5. FDA Approves First Prescription App for Depression — Medscape
6. Rejoyn Becomes First Prescription Digital Therapeutic Authorized for Treatment of MDD — Psychiatric Times

---

Further Reading

• The FDA Has Approved the First App to Help Treat Depression — NPR
• You Can Now Treat Depression With an App — Time
• FDA 510(k) Premarket Notification — K231209 (Rejoyn Device Data)

---

Published on DoctorMentis | Tags: Depression, Digital Health, FDA, Mental Health, Prescription Digital Therapeutics, CBT, MDD